domingo, 13 de septiembre de 2020

Considerations in Advanced Breast Cancer for ER+ and HER2+ Tumors

Considerations in Advanced Breast Cancer for ER+ and HER2+ Tumors

Medscape Logo

Considerations in Advanced Breast Cancer for ER+ and HER2+ Tumors

Sara M. Tolaney, MD, MPH · Harvard Medical School
DISCLOSURES 
December 06, 2019

No hay comentarios:

Publicar un comentario